A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: A hoosier oncology group study

Kristen N. Ganjoo, Michael J. Robertson, William Fisher, Sin Ho Jung, John McClean, Sang Yoon Huh, Jose Bufill, Sheron Williams, Larry D. Cripe

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Gemcitabine is a pyrimidine analog that is active in patients with aggressive lymphomas and Hodgkin disease. This study assessed tumor response in patients with previously treated follicular or small lymphocytic non-Hodgkin lymphoma. This was a 2-stage phase II trial with the first stage requiring 2 of 13 responses to proceed to the second stage. Gemcitabine was given as a single agent to patients with previously treated follicular or small lymphocytic lymphomas. Gemcitabine was administered at 1250 mg/m 2 over 30 minutes on days 1 and 8 of a 21-day cycle for a maximum of 6 cycles. Thirteen patients were treated with 1 to 6 cycles of chemotherapy. Two patients experienced grade 4 toxicity with neutropenia. No grade 4 nonhematologic toxicity was seen. There was 1 partial response and 8 patients (61%) had either minimal response or stable disease. Single-agent gemcitabine administered at this dose and schedule produced 1 partial remission and half the patients had stable disease. However, the study had to be stopped early because of lack of meaningful response.

Original languageEnglish (US)
Pages (from-to)169-172
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume28
Issue number2
DOIs
StatePublished - Apr 1 2005

Keywords

  • Gemcitabine
  • Low-grade lymphoma
  • Non-Hodgkin Lymphoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: A hoosier oncology group study'. Together they form a unique fingerprint.

  • Cite this